2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. MMP
  5. ADAM17 Isoform

ADAM17

 
Cat. No. Product Name Effect Purity
  • HY-115670
    GW280264X
    		Inhibitor 99.30%
    GW280264X is the mixed ADAM10/TACE (ADAM17) metalloproteinases inhibitor. GW280264X potently blocks TACE (ADAM17) and ADAM10 with IC50s of 8.0 nM and 11.5 nM, respectively. ADAM10 and 17 modulate the immunogenicity of glioblastoma-initiating cells.
  • HY-16657
    TAPI-1
    		Inhibitor 99.36%
    TAPI-1 is a broad-spectrum MMP inhibitor and NF-κB p65 inhibitor that targets ADAM17/TACE, ADAM10 and other proteins. TAPI-1 reduces the proteolytic cleavage of membrane-bound TNF-α, decreases TNF-α levels, inhibits NF-κB pathway activation, and downregulates profibrotic markers. TAPI-1 reduces the proportion of proinflammatory immune cells, alleviates cardiac and airway fibrosis, and improves cardiac function after myocardial infarction. Meanwhile, TAPI-1 inhibits the viability, migration and invasion of esophageal squamous cell carcinoma cells, enhances the chemosensitivity of Cisplatin (HY-17394), induces apoptosis, and shows low toxicity to normal esophageal epithelial cells. TAPI-1 can be widely used in studies related to myocardial infarction-induced heart failure, severe traumatic tracheal stenosis, esophageal squamous cell carcinoma and other conditions.
  • HY-110397
    KP-457
    		Inhibitor 99.18%
    KP-457 is a selective a disintegrin and metalloproteinase 17 (ADAM17) inhibitor, with higher selectivity for ADAM17 than for other MMPs and ADAM10, and IC50s are 11.1 nM (ADAM17), 748 nM (ADAM10), 717 nM (MMP2), 9760 nM (MMP3), 2200 nM (MMP8), 5410 nM (MMP9), 930 nM (MMP13), 2140 nM (MMP14), and 7100 nM (MMP17), respectively.
  • HY-10293
    Aderbasib
    		Inhibitor 99.44%
    Aderbasib (INCB007839) is a potent, orally active and target specific low nanomolar hydroxamate-based inhibitor of ADAM10 and ADAM17. Aderbasib exhibits robust antineoplastic activity and can be used for cancer research, including diffuse large B-cell non-Hodgkin lymphoma, HER2+ breast cancer, gliomas, et al.
  • HY-120852
    JG26
    		Inhibitor 98.14%
    JG26 is an ADAM inhibitor with IC50 values of 12 nM, 1.9 nM, and 150 nM for ADAM8, ADAM17, and ADAM10, respectively. JG26 inhibits MMP-12 with an IC50 value of 9.4 nM. JG26 inhibits AngII (HY-13948)-induced EGFR transactivation and ERK activation. JG26 increases the expression of ACE2, inhibits the cleavage of CD23, reduces the infection of SARS-CoV-2. JG26 inhibits colorectal cancer metastasis. JG26 can be used for research on Hodgkin lymphoma and vascular diseases.
  • HY-P992341
    D8P1C1
    		Inhibitor
    D8P1C1 is a high-affinity ADAM17 inhibitor (with a Kd of 180 pM targeting ADAM17-ECD) that reduces the shedding and phosphorylation of EGFR ligands. D8P1C1 inhibits cancer cell proliferation in vitro and tumor growth in xenograft models. 89Zr-DFO-D8P1C1 radioimmunological PET imaging shows its substantial accumulation in ovarian tumor xenografts, serving as a platform for generating bispecific T-cell engager derivatives. D8P1C1 can be applied to research on related diseases including triple-negative breast cancer, various types of ovarian cancer, lung adenocarcinoma, glioma, and colon cancer.
  • HY-P992406
    MEDI-3622
    		Inhibitor
    MEDI-3622 is a human monoclonal antibody against ADAM17. MEDI-3622 blocks the ADAM17-mediated shedding of CD16A and CD62L on NK cells, and binds with high specificity to a surface loop unique to the metalloprotease catalytic domain of ADAM17. MEDI-3622 enhances IFNγ production by NK cells when they bind to antibody-coated tumor cells. MEDI-3622 can be used in the research of ovarian cancer, Burkitt lymphoma, head and neck cancer, and colorectal cancer.
  • HY-P3722A
    Mca-PLAQAV-Dpa-RSSSR-NH2 TFA
    		99.54%
    Mca-PLAQAV-Dpa-RSSSR-NH2 TFA is a fluorescent substrate peptide that can be used to detect ADAM9, ADAM10, and tumor necrosis factor-α converting enzyme (TACE/ADAM17). Mca-PLAQAV-Dpa-RSSSR-NH2 TFA is a fluorescence resonance energy transfer-based substrate, and its activity can be determined by changes in fluorescence intensity upon cleavage (Ex = 320 nm ; Em = 405 nm).
  • HY-P3722
    Mca-PLAQAV-Dpa-RSSSR-NH2
    		Substrate 99.33%
    Mca-PLAQAV-Dpa-RSSSR-NH2 is a fluorescent substrate peptide that can be used to detect ADAM9, ADAM10, and tumor necrosis factor-α converting enzyme (TACE/ADAM17). Mca-PLAQAV-Dpa-RSSSR-NH2 is a fluorescence resonance energy transfer-based substrate, and its activity can be determined by changes in fluorescence intensity upon cleavage (Ex = 320 nm ; Em = 405 nm).
  • HY-175876
    ADAM17-IN-1
    		Inhibitor
    ADAM17-IN-1 is a selective inhibitor of ADAM17. ADAM17-IN-1 inhibits ADAM17 activity to reduce metabolic activity of dendritic cells (DCs), impair DC antigen-presenting function, suppress allergen-specific Th2 cell polarization, and reduce Th2 cytokine (IL-4, IL-5, IL-13) secretion. ADAM17-IN-1 demonstrates protective efficacy against house dust mite (HDM)-induced type 2/eosinophilic airway inflammation in mice. ADAM17-IN-1 can be used for the study of type 2-high allergic asthma.
Cat. No. Product Name / Synonyms Species Source